



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Common Name	TBC
Conjugate	Unconjugated
Synonyms	ABCD-2;CC chemokine TARC;C-C motif chemokine 17;CCL17;chemokine (C-C motif) ligand 17;MGC138273;SCYA17MGC138271;small inducible cytokine subfamily A (Cys-Cys);member 17;Small-inducible cytokine A17;T cell-directed CC chemokine;TARC;TARCA-152E5.3;Thymus and activation-regulated chemokine
Applications	N/A
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
IgG type	IgG2
Reactivity	Human
Target	CCL17
Uniprot ID	Q92583
Description	Anti-CCL17(denrakibart biosimilar) IgG2) mAb
Delivery	3-4 weeks
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

